Drug Profile


Alternative Names: ONO-41483; OP-41483; Tepoprostenol

Latest Information Update: 14 Jun 2000

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Dainippon Pharmaceutical; Ono Pharmaceutical
  • Class Alpha-Cyclodextrins; Anti-ischaemics; Antiasthmatics; Antiplatelets; Heart failure therapies; Prostaglandins
  • Mechanism of Action Epoprostenol agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Arterial occlusive disorders; Asthma; Heart failure; Myocardial ischaemia

Most Recent Events

  • 14 Jun 2000 Discontinued-Clinical for Asthma in Japan (PO)
  • 04 Feb 1997 Discontinued-III for Heart failure in Japan (Unknown route)
  • 30 Jan 1997 Discontinued-III for Myocardial ischaemia in Japan (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top